Back to Market返回行情
KL
KLBF.JK PT Kalbe Farma Tbk.
JKTHealthcare$695.00-3.47%ClosedMarket Cap: $31.45T
As of 2026-06-05 05:11
Valuation
P/E (TTM)
8.69
PEG
—
P/B
1.29
P/S
0.87
EV/EBITDA
5.19
DCF Value
—
FCF Yield
7.8%
Div Yield
2.9%
Margins & Returns
Gross Margin
38.7%
Operating Margin
12.3%
Net Margin
10.0%
ROE
15.6%
ROA
11.3%
ROIC
13.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 2026 | $9.68T | 37.2% | $1.31T | $1.03T | $22.74 | — |
| Q4 2025 | $9.34T | 38.9% | $1.28T | $1.03T | $22.71 | — |
| Q3 2025 | $8.91T | 38.1% | $809.66B | $656.41B | $14.49 | — |
| Q2 2025 | $8.23T | 40.7% | $1.05T | $898.17B | $19.78 | — |
| Q1 2025 | $8.85T | 41.6% | $1.38T | $1.08T | $23.57 | — |
| Q4 2024 | $8.39T | 41.0% | $1.08T | $862.26B | $18.84 | — |
| Q3 2024 | $7.91T | 37.2% | $694.08B | $573.28B | $12.42 | — |
| Q2 2024 | $7.97T | 38.1% | $1.06T | $847.54B | $18.33 | — |
| Q1 2024 | $8.36T | 38.5% | $1.21T | $957.56B | $20.70 | — |
| Q4 2023 | $7.89T | 35.7% | $961.09B | $701.82B | $15.17 | — |
| Q3 2023 | $7.38T | 37.0% | $735.38B | $535.93B | $11.59 | — |
| Q2 2023 | $7.31T | 40.4% | $819.48B | $673.28B | $14.56 | — |